If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
A multiple-sequence FASTA format, or multi-FASTA format, would be obtained by concatenating several single-sequence FASTA files in one file. This does not imply a contradiction with the format as only the first line in a FASTA file may start with a ";" or ">", forcing all subsequent sequences to start with a ">" in order to be taken as separate sequences (and further forcing the exclusive reservation of ">" for the sequence definition line). Thus, the examples above would be a multi-FASTA file if taken together. Modern bioinformatics programs that rely on the FASTA format expect the sequence headers to be preceded by ">". The sequence is generally represented as "interleaved", or on multiple lines as in the above example, but may also be "sequential", or on a single line. Running different bioinformatics programs may require conversions between "sequential" and "interleaved" FASTA formats.
=== Biotransformation === n-Hexane is biotransformed to 2-hexanol and further to 2,5-hexanediol in the body. The conversion is catalyzed by the enzyme cytochrome P450 utilizing oxygen from air. 2,5-Hexanediol may be further oxidized to 2,5-hexanedione, which is neurotoxic and produces a polyneuropathy. In view of this behavior, replacement of n-hexane as a solvent has been discussed. n-Heptane is a possible alternative.
=== Charles and Francis Darwin (1880) === Although known primarily for his work on the Theory of Evolution, Charles Darwin was also keenly interested in plants. Through the 1870s, he and his son Francis studied the movement of plants towards light. They were able to show that light is perceived at the tip of a young stem (the coleoptile), whereas the bending occurs lower down the stem. They proposed that a 'transmissible substance' communicated the direction of light from the tip down to the stem. The idea of a 'transmissible substance' was initially dismissed by other plant biologists, but their work later led to the discovery of the first plant hormone. In the 1920s Dutch scientist Frits Warmolt Went and Russian scientist Nikolai Cholodny (working independently of each other) conclusively showed that asymmetric accumulation of a growth hormone was responsible for this bending. In 1933 this hormone was finally isolated by Kögl, Haagen-Smit and Erxleben and given the name 'auxin'.
U.S. authorities reported a spike in killings, kidnappings, and home invasions connected to Mexican cartels, and at least 19 Americans were killed in 2008. Another 92 Americans were killed between June 2009 and June 2010. The U.S. Joint Forces Command noted in a December 2008 report that the conflict will have a major impact on the stability of the Mexican state over the next several years, and therefore would demand an American response based on the implications for homeland security alone. After the JFC broached this issue in its 2008 report, several journalists and academics have discussed the possibility that Mexico could become a failed state. The Mexican government responded negatively to the U.S. government raising the prospect of Mexico becoming a failed state. To smooth over relations with Mexico over this issue, Secretary of State Hillary Clinton personally visited Mexico City in March 2009, followed by a visit by President Barack Obama a month later.
==== X-ray diffraction ==== A case study by Beale et al. involved preparation of iron phosphates and bismuth molybdate catalysts from an amorphous precursor gel. The study found that there were no intermediate phases in the reaction, and helped to determine kinetic and structural information. The article uses the dated term in-situ, but the experiment uses, in essence, an operando method. Although x-ray diffraction does not count as a spectroscopy method, it is often being used as an operando method in various fields, including catalysis.
Sources: en.wikipedia.org
=== Pharmacodynamics === Pinoline shows affinity for serotonin receptors, including the serotonin 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors (Ki = 156–4,335 nM). It is a high-efficacy partial agonist of the serotonin 5-HT2A receptor, an antagonist of the serotonin 5-HT2B receptor, and a full agonist of the serotonin 5-HT2C receptor, with EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values of 2,140 nM (75%) at the serotonin 5-HT2A receptor and 33 nM (95%) at the serotonin 5-HT2C receptor and an IC50Tooltip half-maximal inhibitory concentration of 1,120 nM at the serotonin 5-HT2B receptor. Hence, pinoline appears to act as a potent and selective serotonin 5-HT2C receptor agonist. The drug shows affinity for the serotonin transporter (SERT) (Ki = 172–572 nM). It is a serotonin reuptake inhibitor, with an IC50 value of 1,100 nM. Pinoline shows affinity for the imidazoline I2 receptor (Ki = 1,640 nM) and for the α2-adrenergic receptor (Ki = 7,830 nM). Conversely, it shows no affinity for the dopamine D2 receptor (Ki = >10,000 nM). The drug is a weak monoamine oxidase inhibitor (MAOI), with an IC50 value for inhibition of MAO-ATooltip monoamine oxidase A of 41,500 nM. Both pinoline and tryptoline partially substitute for the psychedelic drug LSD in rodent drug discrimination tests. The substitution by tryptoline was further assessed and was found to be blocked by the serotonin receptor antagonist pizotifen and by the serotonin synthesis inhibitor para-chlorophenylalanine (PCPA).
As a consequence of the exchange rate policy, the bank must always adjust its interest rates to ensure a stable exchange rate and consequently cannot at the same time conduct monetary policy to stabilize e.g. domestic inflation or unemployment rates. This makes the conduct of stabilization policy fundamentally different from the situation in Denmark's neighbouring countries like Norway, Sweden, Poland and the United Kingdom, in which the central banks have a central stabilizing role. Denmark is presently the only OECD member country maintaining an independent currency with a fixed exchange rate. Consequently, the Danish krone is the only currency in the European Exchange Rate Mechanism II (ERM II), before Bulgaria and Croatia joined in 2020 (the latter uses the euro since 2023) In the first months of 2015, Denmark experienced the largest pressure against the fixed exchange rate for many years because of very large capital inflows, causing a tendency for the Danish krone to appreciate. Danmarks Nationalbank reacted in various ways, chiefly by lowering its interest rates to record low levels. On 6 February 2015 the certificates of deposit rate, one of the four official Danish central bank rates, was lowered to −0.75%. In January 2016 the rate was raised to −0.65%, at which level it has been maintained since then. Inflation in Denmark as measured by the official consumer price index of Statistics Denmark was 1.1% in 2017. Inflation has generally been low and stable for the last decades.
High temperature conditions during the initial stages of implantation will increase the impurity diffusion in the substrate and as a result limit the impinging ion saturation, which is required for nanoparticle nucleation. Both the implant temperature and ion beam current density are crucial to control in order to obtain a monodisperse nanoparticle size and depth distribution. A low current density may be used to counter the thermal agitation from the ion beam and a buildup of surface charge. After implantation on the surface, the beam currents may be raised as the surface conductivity will increase. The rate at which impurities diffuse drops quickly after the formation of the nanoparticles, which act as a mobile ion trap. This suggests that the beginning of the implantation process is critical for control of the spacing and depth of the resulting nanoparticles, as well as control of the substrate temperature and ion beam density. The presence and nature of these particles can be analyzed using numerous spectroscopy and microscopy instruments. Nanoparticles synthesized in the substrate exhibit surface plasmon resonances as evidenced by characteristic absorption bands; these features undergo spectral shifts depending on the nanoparticle size and surface asperities, however the optical properties also strongly depend on the substrate material of the composite.
== ICBM capability, satellites, lunar probes (1955–1960) == The period from 1955 to 1960 saw the first artificial satellites put into earth orbit by both the USSR and the US, the first animals sent into orbit, and the first robotic probes to impact and flyby the Moon by the Soviets.
Pakistan is considered a middle power nation, with the world's seventh-largest standing armed forces in terms of personnel size, comprising approximately 660,000 active-duty troops and 291,000 paramilitary personnel as of 2024. Established in 1947, the armed forces of Pakistan wielded significant influence over national politics. The main branches include the Army, Navy, and Air Force, supported by numerous paramilitaries. The Chairman of the Joint Chiefs of Staff Committee (CJCSC) is the highest-ranking military officer, advising the civilian government. However, they lack direct command over the branches and serve as intermediaries, ensuring communication between the military and civilian leadership. Overseeing the Joint Staff Headquarters, they coordinate inter-service cooperation and joint military missions. Command and control over Pakistan's strategic arsenal development and employment is vested in the National Command Authority, overseeing work on nuclear doctrine to maintain Full spectrum deterrence. The United States, Turkey, and China maintain close military relations with Pakistan Armed Forces, regularly exporting military equipment and technology transfer. Pakistan was the 5th-largest recipient and importer of arms between 2019 and 2023.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.